Investors of Aardvark Therapeutics Can Join Class Action Lawsuit Before October 13, 2026

Aardvark Therapeutics Class Action Lawsuit: Important Deadline for Investors

In a pivotal announcement made by Hagens Berman Sobol Shapiro LLP, a notable national shareholder rights law firm, investors of Aardvark Therapeutics, Inc. (NASDAQ: AARD) have a unique opportunity. Those who have suffered considerable financial losses from their investments in Aardvark are urged to take action and join a shareholder class action lawsuit before the approaching deadline of October 13, 2026. This alert marks a crucial moment for affected investors.

Who Should Participate?

Anyone who purchased or acquired Aardvark common stock from the offering documents related to the company's initial public offering (IPO) held around February 13, 2025, or anyone who bought Aardvark securities between February 13, 2025, and May 14, 2026 (the Class Period) is encouraged to reach out to Hagens Berman. Their inquiry aims to provide assistance and guide investors in their legal rights and potential recovery paths.

Key Details of the Case

The core of the lawsuit revolves around allegations that Aardvark Therapeutics has issued materially false or misleading statements and failed to disclose critical information pertaining to its developmental therapies. Notably, the allegations state that the company's lead drug candidate, ARD-101, aimed at treating hyperphagia in Prader-Willi Syndrome (PWS), was not as safe as the company claimed. Specific issues arose during trials that showed potentially serious, reversible cardiac observations, including QRS prolongation at higher doses, which were not adequately disclosed to investors.

As a result of these revelations, Aardvark's capital raising and commercial potential were grossly overstated. Following a significant announcement on February 27, 2026, that the company would voluntarily pause its Phase 3 HERO trial due to concerning cardiac issues, Aardvark's stock price plunged by over 56%. This downward trend continued when, on May 14, 2026, the FDA placed a complete clinical hold on the investigational new drug application for ARD-101, causing an additional 32.1% drop in stock value.

The Legal Implications

Hagens Berman's investigation into Aardvark’s actions highlights a strong case against the company for misinforming investors and mishandling development protocols concerning ARD-101. Reed Kathrein, a partner at the firm, expressed the importance of addressing these allegations, emphasizing that misleading investors about safety and efficacy can lead to severe implications for investor confidence and regulatory actions.

What Should Investors Do Next?

Affected investors only have until October 13, 2026, to step forward and request to be appointed as Lead Plaintiff for the class action lawsuit. Hagens Berman emphasizes the importance of this opportunity for shareholders to reclaim losses and hold Aardvark accountable for the claimed corporate misconduct. Interested parties are encouraged to submit their information to the law firm promptly for a detailed evaluation of their cases.

Whistleblower Considerations

For those with non-public information about Aardvark Therapeutics, there is also an opportunity to aid in the ongoing investigation or take advantage of the SEC Whistleblower program, wherein whistleblowers can obtain rewards up to 30% of any successful recovery initiated by the SEC. Interested individuals can contact Reed Kathrein at Hagens Berman for more details.

About Hagens Berman

Hagens Berman is a leading plaintiffs' rights firm known for its rigorous focus on corporate accountability. With substantial success in the field, the firm has effectively secured over $2.9 billion in recoveries for various stakeholders, including investors and consumers harmed by corporate negligence. More information about their ongoing cases and the outcomes can be found at hbsslaw.com.

In conclusion, Aardvark Therapeutics investors with financial losses that stem from the company's purported misrepresentations, have until October 13, 2026, to join this class action lawsuit. It’s vital to act quickly and assert your rights in this challenging landscape of corporate accountability.